¿ Aclara BioSciences Inc., of Hayward, Calif., named Wendy Hitchcock chief financial officer and vice president, finance and administration.
¿ Alexion Pharmaceuticals Inc., of New Haven, Conn., named to its board of directors Alvin Parven, president of ASP Associates.
¿ AltaRex Corp., of Waltham, Mass., named Marlene Booth vice president, regulatory affairs and project management.
¿ Ambi Inc., of Purchase, N.Y., appointed to its board of directors Sander Flaum, chairman and CEO of Robert A. Becker Inc. Euro RSCG.
¿ Anika Therapeutics Inc., of Woburn, Mass., promoted Michael Slater to vice president of operations.
¿ ArgoMed Inc., of Research Triangle Park, N.C., appointed Richard Klein president and CEO.
¿ Atrix Laboratories Inc., of Fort Collins, Colo., elected to its board of directors Richard Jackson, senior vice president, research and development.
¿ Aurora Biosciences Corp., of San Diego, appointed Stuart Collinson as president.
¿ Chiroscience Group plc, of Cambridge, U.K., appointed Enda Gribbon, business development manager in the U.K., and Mark Litton, director of business development in the U.S.
¿ Demegen Inc., of Pittsburgh, named to its board of directors Robert Hannan, principal and CEO of The Genesis Group.
¿ Entropin Inc., of Woodland Hills, Calif., named Donald Hunter, chief executive officer and treasurer.
¿ Genometrix Inc., of The Woodlands, Texas, appointed Deval Lashkari vice president of marketing and business development.
¿ Gensia Sicor Inc., of Irvine, Calif., appointed Frank Becker, executive vice president and chief operating officer, and Michael Cannon, executive vice president and chief scientific officer.
¿ GenVec Inc., of Rockville, Md., named Jeffrey Church chief financial officer; Richter King, vice president of research; and Henrik Rasmussen, vice president of clinical and regulatory affairs.
¿ ImmunoGen Inc., of Norwood, Mass., appointed Pauline Ryan senior director of business development.
Inspire Pharmaceuticals Inc., of Durham, N.C., promoted Richard Evans to senior director, pharmaceutical development, and William Pendergast to senior director, chemistry.
¿ MediChem Research Inc., of Lemont, Ill., named to its board of directors Larry Hansen, senior vice president, preclinical development, for G. D. Searle and Co.
¿ Millennium Pharmaceuticals Inc., of Cambridge, Mass., named Jack Douglas, general counsel.
¿ Molecumetics Ltd., of Seattle, hired Yat Sun Or as vice president, medicinal chemistry.
¿ Phytera Inc., of Worcester, Mass., appointed Nancy Wetherbee, vice president of business development.
¿ Protein Design Labs Inc., of Fremont, Calif., promoted Glen Sato to vice president and general counsel.
¿ Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., appointed William Roberts vice president, regulatory development.
¿ Ribozyme Pharmaceuticals Inc., of Boulder, Colo., appointed Wayne Cowens vice president of clinical and regulatory affairs.
¿ SafeScience Inc., of Boston, appointed Clark Springgate chief medical officer.
¿ Sofinov, of Montreal, appointed Jean-Christophe Renondin vice president, biotechnology and health care.
¿ Sugen Inc., of South San Francisco, named Bruce MacMillan vice president, general counsel and corporate secretary.
¿ Symbiontics Inc., of St. Louis, named to its board of directors Constantine Anagnostopoulos, managing general partner of Gateway Associates of St. Louis.
¿ Synsorb Biotech, of Calgary, Alberta, appointed to its board of directors Andre Pernet, former vice president, pharmaceutical products research and development for Abbott Laboratories.